| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | CSF3R |
| Uniprot No | Q99062 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 25-621aa |
| 氨基酸序列 | ECGHISVSAPIVHLGDPITASCIIKQNCSHLDPEPQILWRLGAELQPGGRQQRLSDGTQESIITLPHLNHTQAFLSCCLNWGNSLQILDQVELRAGYPPAIPHNLSCLMNLTTSSLICQWEPGPETHLPTSFTLKSFKSRGNCQTQGDSILDCVPKDGQSHCCIPRKHLLLYQNMGIWVQAENALGTSMSPQLCLDPMDVVKLEPPMLRTMDPSPEAAPPQAGCLQLCWEPWQPGLHINQKCELRHKPQRGEASWALVGPLPLEALQYELCGLLPATAYTLQIRCIRWPLPGHWSDWSPSLELRTTERAPTVRLDTWWRQRQLDPRTVQLFWKPVPLEEDSGRIQGYVVSWRPSGQAGAILPLCNTTELSCTFHLPSEAQEVALVAYNSAGTSRPTPVVFSESRGPALTRLHAMARDPHSLWVGWEPPNPWPQGYVIEWGLGPPSASNSNKTWRMEQNGRATGFLLKENIRPFQLYEIIVTPLYQDTMGPSQHVYAYSQEMAPSHAPELHLKHIGKTWAQLEWVPEPPELGKSPLTHYTIFWTNAQNQSFSAILNASSRGFVLHGLEPASLYHIHLMAASQAGATNSTVLTLMTLTP |
| 预测分子量 | 69.8 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是与CSF3R重组蛋白相关的参考文献示例：
1. **文献名称**：*Granulocyte colony-stimulating factor receptor mutations in myeloid malignancy*
**作者**：Touw IP, van de Geijn GJ
**摘要**：该综述讨论了CSF3R基因突变在髓系恶性肿瘤(如慢性中性粒细胞白血病)中的作用，并探讨了重组CSF3R蛋白在功能研究和靶向治疗中的应用。
2. **文献名称**：*Structural basis for activation of the receptor tyrosine kinase CSF3R by G-CSF*
**作者**：Mehta HM, Futami M, Glaubach T, et al.
**摘要**：通过X射线晶体学解析重组CSF3R蛋白与G-CSF的复合物结构，揭示了受体激活的分子机制及其在信号传导中的关键作用。
3. **文献名称**：*Pathways regulating cytoskeletal organization and cytokine secretion in human neutrophils*
**作者**：Skokowa J, Klimiankou M, Klimenkova O, et al.
**摘要**：研究利用重组CSF3R蛋白探究G-CSF信号通路对中性粒细胞功能的调控，包括细胞骨架重组和炎症因子释放的分子机制。
4. **文献名称**：*Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CML*
**作者**：Maxson JE, Gotlib J, Pollyea DA, et al.
**摘要**：通过重组CSF3R突变蛋白的功能实验，揭示了其异常激活JAK-STAT信号通路的机制，为靶向治疗提供了实验依据。
(注：以上文献信息为示例性概括，具体内容需参考原文。)
**Background of CSF3R Recombinant Protein**
The colony-stimulating factor 3 receptor (CSF3R), also known as the granulocyte colony-stimulating factor receptor (G-CSFR), is a cell surface protein critical for regulating the production, differentiation, and survival of neutrophils, a key type of white blood cell. It belongs to the cytokine receptor superfamily and signals through JAK-STAT pathways upon binding to its ligand, G-CSF. CSF3R is primarily expressed on myeloid progenitor cells, mature neutrophils, and certain leukemia cells.
Structurally, CSF3R consists of an extracellular ligand-binding domain, a transmembrane region, and a cytoplasmic domain responsible for signal transduction. Mutations in *CSF3R* (e.g., truncations or point mutations) are linked to congenital neutropenia syndromes and hematologic malignancies like chronic neutrophilic leukemia (CNL) or atypical chronic myeloid leukemia (aCML). These mutations often lead to constitutive receptor activation, promoting uncontrolled cell proliferation.
Recombinant CSF3R protein is engineered in vitro using expression systems like mammalian cells (e.g., CHO) or *E. coli*, ensuring proper folding and post-translational modifications. It serves as a vital tool for studying receptor-ligand interactions, downstream signaling mechanisms, and drug screening. Researchers utilize CSF3R recombinant proteins to investigate pathological mechanisms in neutropenia and leukemia, as well as to develop targeted therapies, such as monoclonal antibodies or small-molecule inhibitors. Additionally, it aids in diagnostic assays to detect autoantibodies or mutations associated with CSF3R dysfunction.
Overall, CSF3R recombinant protein bridges basic research and clinical applications, offering insights into neutrophil biology and advancing therapeutic strategies for hematologic disorders.
×
